Equillium, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a EQ research report →
Range $5 – $7
Price Chart
About the company
Equillium, Inc. is a clinical-stage biopharmaceutical company focused on developing and bringing to market products designed to address severe autoimmune and inflammatory (immuno-inflammatory) disorders where current treatment options are insufficient. The company's primary drug candidate is itolizumab (EQ001), a monoclonal antibody in clinical development that targets the novel CD6 immune checkpoint receptor.
- CEO
- Bruce D. Steel
- IPO
- 2018
- Employees
- 14
- HQ
- La Jolla, CA, US
Get TickerSpark's AI analysis on EQ
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $142.58M
- P/E
- -8.80
- PEG
- -0.14
- P/S
- 0.00
- P/B
- 4.50
- EV/EBITDA
- -4.69
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -41.15%
- ROIC
- -34.10%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $-116,000-100.3%
- Op Income
- $-23,634,000
- Net Income
- $-22,398,000-177.6%
- EPS
- $-0.39-69.6%
- OCF Growth
- -19.6%
- FCF Growth
- -19.3%
- 52W High
- $3.54
- 52W Low
- $0.76
- 50D MA
- $2.62
- 200D MA
- $1.92
- Beta
- 1.81
- RSI (14)
- 46
- Avg Volume
- 879.76K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
EMBARQ posted solid Q1 2009 results with strong cash flow, improving consumer line trends, and steady progress toward its CenturyTel merger.· May 7, 2009
- Revenue fell 7.6% year over year to $1.35 billion, but operating income held up at $410 million and EPS from continuing operations reached $1.39.
- Cash flow before dividends hit a record $339 million, helped by only $105 million of CapEx and lower capital needs.
- Consumer access line losses improved to nearly prior-year levels, while HSI net adds rose to 40,000 and HSI revenue grew more than 7%.
- Management said FCC approval remains pending in 5 of 33 states and still expects all necessary merger approvals in Q2.
- The company said Q2 should look similar to Q1, with revenue decline possibly moderating and cash flow staying above prior-year levels.
First-quarter revenue declined 7.6% year over year to $1.35 billion. Operating income was $410 million, down 6% from $436 million a year earlier, and operating margin improved to 30.5%. Diluted EPS from continuing operations was $1.39, while total diluted EPS was $1.21 after the EMBARQ Logistics sale; the sale also included a $24 million loss and a $2 million loss related to pre-close results. Cash flow before dividends was a record $339 million, up from $287 million in the year-ago period, and CapEx was $105 million. For guidance, management said Q2 should look very much like Q1, with revenue decline potentially moderating a bit, cash flow before dividends expected to remain above prior year, and CapEx expected to rise sequentially in Q2 but stay well below last year.
Tom Gerke framed the quarter as a successful start to 2009 despite a weak economy, emphasizing that EMBARQ preserved strong cash flow and made clear progress on the CenturyTel merger. He highlighted improving consumer line-loss trends, better HSI net adds, and ongoing work on integration readiness, saying the teams were well positioned for approval and execution after close. His tone was constructive and confident, while still acknowledging economic pressure on the top line.
Gene Betts focused on profitability and cash generation, saying earnings per share from continuing operations and cash flow before dividends were at their highest levels ever. He noted operating income of $410 million, operating margin of 30.5%, and EPS from continuing operations of $1.39, with expense declines driven by lower cost of products, depreciation, and personnel expense from prior workforce reductions. He also pointed to record cash flow before dividends of $339 million, CapEx of $105 million, and expected Q2 cash flow to remain above prior year, though CapEx should increase seasonally and remain below 2008 levels.
Analysts pressed for confidence around the expected Q2 improvement, asking whether monthly revenue trends support the outlook and whether broadband growth depended on promotions. Management said the revenue outlook mainly reflects better access-line trends and some other revenue categories improving, while HSI growth was driven more by base management and churn improvement than by unusual promotional activity. Questions also focused on margins and CapEx; management attributed margin improvement largely to headcount reductions and broader business-process gains, and said CapEx was running light because of fewer required new service addresses and disciplined targeting.
The quarter showed EMBARQ can still generate strong earnings and record cash flow despite revenue pressure, which management tied to expense discipline and lower capital needs. Consumer line losses improved meaningfully, HSI net adds recovered, and management said merger approvals were still on track for Q2, suggesting operational stability going into the close.
The business still faced clear economic headwinds: revenue fell 7.6%, access lines declined by 144,000, and business-market disconnects rose due to weaker demand and bankruptcies. New orders remained soft across consumer and business, special access was weak, and management said Q2 would likely only be similar to Q1 rather than showing a strong rebound.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 55.9%
- Shares Outstanding
- 63.23M
- Float Shares
- 35.35M
of shares held by institutions
41 13F filers
Buy/sell ratio 0.80. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Janus Henderson Group PLC | 6.49M | ▲ 632.36K |
| Vanguard Group Inc | 1.92M | ▲ 606.48K |
| Takeda Pharmaceutical Co Ltd | 1.82M | 0 |
| Cota Capital Management, LLC | 562.28K | 0 |
| Two Sigma Advisers, LP | 44.10K | ▲ 44.10K |
Held by 27 ETFs
Biggest fund positions in EQ by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 5, 26 | Zedelmayer Christine | other | 14,584 |
| Jun 5, 26 | Zedelmayer Christine | sell | 14,584 |
| Jun 5, 26 | Zedelmayer Christine | other | 14,584 |
| Jun 4, 26 | Connelly Stephen | sell | 200,000 |
| Jun 5, 26 | Connelly Stephen | sell | 30,975 |
| May 28, 26 | Tom Penny | other | 65,000 |
| May 28, 26 | Tom Penny | sell | 65,000 |
| May 28, 26 | Tom Penny | other | 65,000 |
| May 28, 26 | DEMSKI MARTHA J | other | 70,000 |
| May 28, 26 | Pruzanski Mark | other | 70,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our EQ coverage
Recent articles, reports, and earnings notes.
No research on EQ yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate EQ report →Equillium Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
globenewswire.com · Aug 13
Equillium, Inc. (NASDAQ:EQ) Given Consensus Recommendation of “Moderate Buy” by Analysts
defenseworld.net · Aug 10
EQ Works Expands Multi-Year Partnership with Leading Canadian Publisher to Include SaaS License for ClearLake
accessnewswire.com · Jun 18
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Jun 2
Equillium, Inc. (EQ) Discusses Mechanistic Insights Linking AhR Signaling and miR-124 in Inflammatory Disease Transcript
seekingalpha.com · Jun 1
Equillium Links AhR Activation to miR-124 as EQ504 Heads Toward Phase 1
marketbeat.com · May 29
Equillium to Participate in the 2026 Jefferies Global Healthcare Conference
globenewswire.com · May 28
Equillium to Host Virtual Investor Event to Share New Insights into the Aryl Hydrocarbon Receptor (AhR) and miR-124 Axis
globenewswire.com · May 20
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.